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Angiogenesis is important for the progression of cutaneous melanoma. Here, we analyzed
the prognostic impact of the angiogenic factor urokinase plasminogen activator resecptor
(uPAR), vascular proliferation index (VPI) and tumor necrosis as a measure of hypoxia in a
patient series of nodular melanomas (n = 255) and matched loco-regional metastases (n =
78). Expression of uPAR was determined by immunohistochemistry and VPI was assessed
by dual immunohistochemistry using Factor-VIII/Ki67 staining. Necrosis was recorded
based on HE-slides. As novel findings, high uPAR expression and high VPI were associated
with each other, and with increased tumor thickness, presence of tumor necrosis, tumor
ulceration, increased mitotic count and reduced cancer specific survival in primary mela-
noma. In matched cases, VPI was decreased in metastases, whereas the frequency of
necrosis was increased. Our findings demonstrate for the first time the impact on melanoma
specific survival of uPAR expression and VPI in primary tumors, and of increased necrosis
as an indicator of tumor hypoxia in loco-regional metastases. These findings support the
importance of tumor angiogenesis in melanoma aggressiveness, and suggest uPAR as an
indicator of vascular proliferation and a potential biomarker in melanoma.
Introduction
Angiogenesis is the formation of new capillaries from existing blood vessels, and sustained
angiogenesis is a pathological feature in tumors as proposed by Folkman in 1971 [1]. Today,
angiogenesis is regarded as a hallmark of cancer [2], and microvessel density (MVD) was
introduced as a method of morphological assessment of intra-tumor neovascularization in
1991 [3].
In melanoma, angiogenesis is involved in tumor progression and metastasis [4, 5], and
MVD has been shown to be an adverse prognostic factor [6–8]. Recently, vascular proliferation
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index, VPI, has been introduced as a novel angiogenesis marker showing superior prognostic
value compared to MVD in endometrial, prostate, breast and lung cancer [9–12]. The hypoth-
esis is that this method captures the actively expanding vasculature better than standard micro-
vessel density, and that tumors with a higher VPI are more aggressive with poorer prognosis.
Previously, proliferating endothelial cells was suggested as a prognostic factor in a small series
of primary melanoma [13], and in a cohort of melanoma sentinel lymph node metastases [14].
Urokinase plasminogen activator receptor (uPAR) has a proteolytic function as a degrader
of extracellular matrix [15], and it has been associated with invasion and metastasis in mela-
noma [16–21]. In addition, uPAR support endothelial cell proliferation, migration and perme-
ability [22–24]. Whereas uPAR has shown prognostic value in different types of cancer, the
association with survival has not been analyzed in melanoma [25–30].
The prognosis for stage III melanoma is heterogenous, with 10-year survival rates varying
from 24–88% [31]. Presence of necrosis, related to tumor hypoxia and a prognostic histopatho-
logic characteristic previously demonstrated for primary melanoma by our group [32, 33], has
not been investigated as a survival marker in metastatic melanoma.
Here, we studied for the first time the presence and prognostic significance of uPAR expres-
sion in cutaneous melanoma, and whether vascular proliferation by VPI was associated with
uPAR, tumor necrosis, and melanoma specific survival. We also examined potential differ-
ences between primary tumors and matched loco-regional metastases.
Material and methods
Patients
This patient series consists of 255 consecutive cases of primary nodular cutaneous melanomas
diagnosed at the Department of Pathology, Haukeland University Hospital (Bergen, Norway)
during 1998–2008 [34, 35]. The presence of a vertical growth phase and absence of a radial
growth phase, i.e. adjacent in situ or microinvasive components, were used as inclusion crite-
ria. Cases with minor secondary involvement of the adjacent epidermis up to three epidermal
ridges were included. There was no known history of familial occurrence. During this time
period, the sentinel node procedure was not performed in Norway, and our series therefore
lacks complete staging. Median age was 70 years, and the median primary tumor thickness
was 3.6 mm (range 0.7–29.0 mm). Complete information on patient survival, time and cause
of death was available in all 255 cases. Last date of follow-up of survival, with information on
cause of death from the Cancer Registry of Norway, was December 31, 2014. Median follow-
up time for survivors was 115 months (range 72–203 months). During the follow-up period,
88 patients (35%) died of malignant melanoma and 76 (30%) died of other causes. Last date of
follow-up of recurrent disease, including information from medical records, was February 29,
2016. A summary of patient characteristics is given in S1 Table.
In addition, 78 paired biopsies from the first appearing local (skin; n = 26) or regional meta-
static tumor (lymph nodes; n = 52) in this series were examined. In cases with multiple metas-
tases at the same time within the same organ compartment, we have selected the largest tumor.
If the largest metastasis contained necrosis to the extent that representative tissue could not be
sampled, then the largest tumor without such necrosis was chosen. Of the 78 cases with metas-
tases, HE-slides of tissue biopsies were available in 73 cases (n = 25 skin metastases, n = 48
lymph node metastases), while in five cases only HE-slides of core needle biopsies were avail-
able. Further, due to limited tumor tissue in the paraffin blocks, 69 of the 73 cases were avail-
able for whole slide immunohistochemistry, and 68 of the 73 cases were available for tissue
microarrays.
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Clinico-pathologic variables
Clinical data and histologic variables of primary melanoma were included: date of histologic
diagnosis, sex, age at diagnosis, tumor anatomic site, tumor thickness according to Breslow
[36], level of invasion according to Clark [37], mitotic count, the mitotic marker PHH3 [38],
microscopic tumor ulceration [38] and tumor necrosis [32].
For all loco-regional metastases, clinical data on date of histologic diagnosis and site of first
metastasis were registered. All slides of the loco-regional metastases were examined (EH,
LAA) and the following histologic variables were recorded: maximum tumor diameter and
tumor necrosis [32]
Tissue microarray (TMA)
The TMA technique has been described and validated in several studies [39–41]. Three tissue
cylinders (diameter 1.0 mm) from representative tumor areas identified on H&E stained slides,
such as the supra-basal area of the primary melanomas, were punched from archival blocks
and mounted into a recipient paraffin block using a custom made precision instrument (for
TMAs of primary melanoma: Beecher Instruments, Silver Spring, MD, USA, for TMAs of mel-
anoma metastases: Minicore 3, Tissue Arrayer, Alphelys, France). Sections (5 μm) of the result-
ing TMA blocks were made by standard technique.
uPAR immunohistochemistry
The immunohistochemical staining was performed on 5 μm TMA sections of paraffin-embed-
ded archival tissue. Sufficient tumor tissue for immunohistochemistry was available in 248 of
the primary melanoma cases and 68 of the loco-regional metastatic melanomas. The slides were
dewaxed with xylene/ethanol. Antigen retrieval was performed for 20 minutes in Target
Retrieval Solution (DAKO 1699) (pH = 6) in microwave. Endogenous peroxidase activity was
prevented by treating the slides with peroxidase block (DAKO S2001) for 8 minutes. The slides
were incubated with the mouse monoclonal antibody uPAR (dilution 1:100) (ADG 3937, Seki-
sui Diagnostics, Pfungstadt, Germany) overnight at 4˚C. EnVision labelled polymer method
was then used (DAKO K4001 or K4003) for 30 minutes. 3-amino-9-ethylcarbazole (AEC)
(DAKO K3469) was used as substrate chromogen. Brief counterstaining was performed with
hematoxylin (DAKO S2020). Negative control was obtained by omitting the primary antibody.
Dual Factor-VIII/Ki67immunohistochemistry
The immunohistochemical staining was performed on 5 μm sections of paraffin-embedded
archival tissue. Sufficient tumor tissue for immunohistochemistry was available in 242 of the
primary melanomas and 69 of the paired loco-regional metastases. Staining was first per-
formed in primary melanoma by IMB, and the staining protocol was adjusted (antibody dilu-
tion and incubation time) to obtain an optimal result when metastases were subsequently
stained by EH. The slides were dewaxed with xylene/ethanol before microwave antigen
retrieval for 20 minutes in Target Retrieval Solution (DAKO 1699) (pH = 6). Endogenous per-
oxidase activity was prevented by treating the slides with peroxidase block (DAKO S2001) for
8 minutes. The slides were simultaneously incubated with the two antibodies Factor-VIII
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(polyclonal rabbit antibody, DAKO A0082) (dilution 1:500 for primary melanoma and 1:1000
for metastases) and Ki67 (monoclonal mouse antibody, DAKO M7240) (dilution 1:200 for pri-
mary melanoma and 1:50 for metastases) for 60 minutes in primary melanoma and 90 minutes
in metastases. The staining procedure was performed using the secondary goat anti-mouse
antibody (1031–04, Southern Biotech, Birmingham, AL, USA) diluted in anti-rabbit EnVision
labelled polymer method (DAKO K4003) at 1:100 for 30 minutes. Visualization was done with
the Ferangie Blue TM Chromagen System (Biocare Medical, Concord, CA, USA) (applied for
20 minutes) for Ki67 and with 3-amino-9-ethylcarbazole (AEC) (DAKO K3469) as substrate
chromogen for Factor-VIII (applied for 10 minutes). No counterstaining was applied. Negative
controls were obtained by omitting the primary antibody.
Evaluation of uPAR expression
Expression of uPAR was characterized by membrane-associated staining of melanoma cells.
The staining intensity was recorded as either negative, weak, moderate or strong (0–3). Propor-
tion of tumor cells stained was recorded as either 1 (< 10%), 2 (10–50%) or 3 (> 50%). A stain-
ing index (SI) was calculated as the product of staining intensity and area score (proportion of
tumor cells stained) [42]. For additional evaluation of the staining, a subset of cases (n = 54) was
scored blindly by two observers (EH, RGL) showing good inter-observer agreement (κ = 0.63,
p< 0.01). Evaluation of the cases was done blinded for patient characteristics and outcome.
Evaluation of microvessel density (MVD) and vascular proliferation index
(VPI)
In tumor tissue sections, blood vessel endothelial cells were visualized using immunohistochemis-
try for both an endothelial marker (Factor-VIII) and a proliferation marker (Ki67). The tissue
sections were examined at low magnification to identify the most vascular areas of the tumor
(“hot-spots”). In primary melanoma, the hot-spot regions were almost exclusively localized
around the invasive front at the tumor base. In melanoma metastases, the hot-spot area was
marked by a pathologist (LAA). Within these hot-spots, a maximum of 10 fields at x 400 were
examined and the number of vessels counted (MVD). Minimum one-half of the high power field
(HPF) (x400) must contain viable tumor cells. Vessels more than one-half HPF (x400) below the
invasive front, or vessels close (< 1 HPF) to ulcerated or necrotic areas were not counted. Any
highlighted endothelial cell or cell cluster clearly separate from adjacent microvessels were
regarded as a distinct countable microvessel. In addition, the number of proliferating vessels were
recorded in the same 10 fields within the hot-spot by counting the number of vessels with endo-
thelial cells co-expressing the endothelial and the proliferation markers (pMVD). VPI is defined
as the ratio between the number of proliferating vessels and the total number of vessels. MVD
and pMVD was assessed by IMB in primary melanoma, and by EH in the melanoma metastases.
To compensate for any inter-observer difference, 25 of the primary melanomas were
assessed for MVD and pMVD also by EH. The vessel counts showed good inter-observer
agreement (κ = 0.68, p< 0.01 for MVD, κ = 0.61, p< 0.01 for pMVD and κ = 0.84, p< 0.01
for VPI). The median values for MVD, pMVD and VPI among the 25 primary melanomas
counted by EH were then compared to IMBs median values, and a ratio was calculated for
MVD (1.17), pMVD (1.03) and VPI (0.91) (S2 Table). These ratios were then used as correc-
tion factors on IMBs counts for MVD, pMVD and VPI in primary melanoma.
Statistics
Statistical analyses were performed using the IBM Statistical package for the Social Sciences
version 23 (IBM Corp. Armonk, NY). Associations between different categorical variables
uPAR Expression and angiogenesis in melanoma
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were assessed by the Pearson’s chi-square test. Comparison of two or more continuous vari-
ables not following the normal distribution was performed using the Mann-Whitney U or
Kruskal-Wallis tests. Differences between paired samples were determined by the McNemar
test for categorical data and Wilcoxon test for continuous variables. Kappa (κ) statistics was
used in analyses of inter-observer agreement of categorical data.
Univariate analyses of time to death due to malignant melanoma were performed using the
product-limit procedure (Kaplan-Meier method), and differences between categories were esti-
mated by the log-rank test, with date of histological diagnosis as the starting point for analyses of
primary melanomas and date of first metastasis as the starting point for analyses of metastatic
melanomas. Patients who died of other causes were censored at the date of death. The influence
of co-variates on patient survival was analyzed by the proportional hazards method, and tested by
the likelihood ratio (lratio) test. The variables were tested by log-log plot to determine their ability
to be incorporated in multivariate models. All results were considered significant if p< 0.05.
In the statistical analyses, the cut-off points for categorization of staining index data were
determined after considering the frequency distribution curve, size of possible subgroups and
number of events. The cut-off points for categorization of continuous variables were deter-
mined after considering the survival curve patterns of the quartiles. As a rule, subgroups with
similar survival were merged. When one quartile‘s survival curve diverged from the three
other survival curves, the cut-off was set at this quartile. In the case of an even distribution of
survival curves, or a divergence between the survival curves of the two lowest quartiles versus
the two highest quartiles, the median was used as cut-off point.
Results
Expression of uPAR in primary and metastatic tumors
Immunohistochemical staining obtained by the uPAR antibody was assessed in primary mela-
nomas (n = 248) and 68 paired loco-regional metastases. The staining was membrane-associ-
ated and generally homogenous, and differences in staining intensity between tumor areas
(heterogeneity) were rarely observed. Protein expression was categorized according to the
staining index (SI) as either negative/low or positive/high, with a cut-off value based on the
median (uPAR; SI = 4) in primary melanomas (Fig 1).
Fig 1. uPAR expression. Immunohistochemical staining of a uPAR positive primary melanoma (a) (x400) and a uPAR expression negative
loco-regional metastasis (b) (x 400).
https://doi.org/10.1371/journal.pone.0210399.g001
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Positive uPAR expression in primary melanoma was associated with increased VPI
(p = 0.01), increased tumor thickness (p< 0.01), presence of tumor ulceration (p = 0.03),
increased mitotic count (p< 0.01) and presence of tumor necrosis (p = 0.01) (Table 1).
In loco-regional metastases, uPAR was significantly associated with increased MVD
(p< 0.05; Mann -Whitney test), but not with VPI (S3 Table).
Regarding differences between primary tumors and the first appearing loco-regional metas-
tasis (n = 65), uPAR expression was not significantly different in metastases compared to pri-
mary tumors, although it tended to be lower (p = 0.27; McNemar test) (S4 Table).
Angiogenesis markers in primary and metastatic tumors
In primary melanoma (n = 242), median MVD was 62/mm2, pMVD 6.1/mm2 and VPI 9.6%.
In loco-regional metastases (n = 69), median MVD was 95/mm2, pMVD 9.0/mm2 and VPI
7.6% (Table 2). For information on MVD, pMVD and VPI specifically in skin or lymph node
metastases, see Table 2. MVD, pMVD and VPI in primary and metastatic melanoma were
Table 1. uPAR protein expression in association with vascular proliferation index (VPI) and histopathologic





Tumor thickness (mm) < 0.01b
median 3.0 4.5
Tumor ulcerationd 0.03e
absent (n) 70 43
Present (n) 62 67
Mitotoc count (per mm2) < 0.01b
median 2.8 8.0
Tumor necrosis 0.01e
absent (n) 110 75
present (n) 24 37







Table 2. Distribution of MVD, pMVD and VPI in primary (n = 242) and metastatic (n = 69) melanoma.






median (no/mm2) 62.3 95.0 91.3 98.7
pMVD
median (no/mm2) 6.1 9.0 7.8 10.0
VPI
median (%) 9.6 7.6 11.1 7.4
https://doi.org/10.1371/journal.pone.0210399.t002
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categorized as either low or high based on the median (MVD and pMVD) or the lower quartile
(VPI, 5.7%) in primary tumors (Fig 2). Median pMVD was significantly higher among pri-
mary melanoma with loco-regional metastasis (pMVD = 7.6) than among cases without
metastasis (pMVD = 5.6) (p = 0.024, Mann Whitney U test), whereas there were no significant
differences for MVD or VPI (S5 Table).
There was sufficient tumor tissue in both the primary and matched metastatic lesions in 67
cases. Among these, median MVD was significantly higher in metastases: 97/mm2 versus 67/
Fig 2. Vascular proliferation. IHC dual staining with Factor-VIII and Ki67 showing proliferating vessels in primary
melanoma (a) (x400) and loco-regional metastasis (b) (x400).
https://doi.org/10.1371/journal.pone.0210399.g002
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mm2 in primary melanoma (p< 0.01). The opposite was found for VPI, which had signifi-
cantly lower median value in metastases; 7.6% versus 11.0% in primary melanoma (p< 0.05),
whereas there was no significant difference in median pMVD between primary melanomas
and paired metastases (p = 0.36). A similar pattern was found among the 44 cases of paired pri-
mary and lymph node tumors, while among the 23 cases with paired primary and skin tumors
there was no significant reduction of VPI in metastases (S6 Table).
Increased VPI in primary melanomas was significantly associated with features of aggres-
sive tumors, like increased tumor thickness (p< 0.01), presence of tumor ulceration
(p< 0.01), high mitotic count (p< 0.01) and presence of tumor necrosis (p< 0.01) (Table 3).
Tumor necrosis in loco-regional metastases
In this study, tumor necrosis was focused due to its known association with tumor hypoxia,
and also because it is a prognostic factor in primary melanoma [32, 33]. Of the 78 matched
and first appearing loco-regional metastases, 26 were from skin/subcutaneous tissue, and 52
were lymph-node metastases. All variables were recorded based on HE-slides of tissue biopsies
(n = 73; 25 skin metastases and 48 lymph node metastases).
Data on tumor necrosis was available in both the primary tumor and the corresponding
metastasis in 73 cases. Of these 73 matched cases, 25 cases consisted of primary tumor and cor-
responding skin metastasis, while the remaining 48 cases consisted of primary tumor and cor-
responding lymph node metastasis. Among matched cases, tumor necrosis was present in 23
(23 out of 73, 32%) of the primary tumors, compared to 41 (41 out of 73, 56%) of the metastatic
tumors (p < 0.01, McNemar test) (S7 Table) (Fig 3).
In skin metastases, the median tumor diameter was 8 mm (range 1–30), and necrosis was
present in 8 cases (32%). In lymph node metastases, median tumor diameter was 30 mm
(range 1–80) and necrosis was present in 33 cases (69%). Regarding tumor size, necrosis was
associated with tumor diameter in skin metastases (p = 0.002), and tended to show a similar
association in lymph node metastases (p = 0.055) (Table 4).
Table 3. VPI in association with histopathologic characteristics of primary melanoma (n = 242).
VPI (median) p-value
Tumor thickness (mm) < 0.01b
< 2.0 mm 5.2
2.0–4.1 mm 9.5
> 4.0 mm 13.5
Tumor ulceration < 0.01c
absent 6.4
present 13.2
Mitotic count (per mm2)a < 0.01c
low 7.5
high 10.5
Tumor necrosis < 0.01c
absent 8.3
present 14.5
aCut-off point: lower quartile
b Kruskal Wallis test
cMann -Whitney U test
https://doi.org/10.1371/journal.pone.0210399.t003
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Presence of necrosis was significantly associated with higher VPI in lymph node metastases
(p = 0.015), but not in skin metastases (Table 4). There were no significant associations
between tumor diameter and VPI in skin- or lymph node metastases (S8 Table).
Analysis of patient survival
Positive uPAR expression in primary tumors was associated with reduced melanoma-specific
survival in univariate analysis (p = 0.03; log-rank test), and showed a similar tendency in meta-
static melanoma (p = 0.19, log-rank test) (Fig 4). There was no independent prognostic value
of uPAR expression in multivariate analysis (S9 Table).
Fig 3. Tumor necrosis. Presence of tumor necrosis in HE-slides of a loco-regional skin metastasis (a) (x 400) and a
loco-regional lymph node metastasis (b) (x 40).
https://doi.org/10.1371/journal.pone.0210399.g003
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VPI in primary melanoma was associated with reduced survival in univariate analysis
(p = 0.002; log-rank test), but was not an independent prognostic factor in multivariate analy-
sis when included together with tumor thickness, ulceration, mitotic count and tumor necrosis
(S10 Table). There was a similar tendency in univariate analysis of metastatic melanoma,
although not significant (p = 0.19, log-rank test) (Fig 5).
Presence of necrosis in melanoma metastases was significantly associated with reduced sur-
vival, both when analyzed in all loco-regional metastases (n = 73) (p = 0.003), when analyzed
in skin metastases (n = 25) (p = 0.02) and when analyzed in lymph node metastases (n = 48)
(p = 0.008) (Fig 6).
Maximum tumor diameter showed a borderline prognostic value in skin metastases
(p = 0.06) (lymph node metastases, p = 0.26) (S1 Fig).
Discussion
We analyzed for the first time a relationship between the vascular proliferation index (VPI), a
novel tissue-based angiogenesis marker, and melanoma-specific patient survival, using a large
cohort of primary tumors and matched loco-regional metastases. Here, we found a significant
impact of VPI on melanoma survival, suggesting that neo-angiogenesis is an aggressive feature
of the melanoma microenvironment. This is supported by consistent associations between
VPI and high-grade characteristics of the primary tumor: increased tumor thickness, tumor
ulceration, higher mitotic count and presence of tumor necrosis. Our finding is in line with a
previous report of proliferating endothelial cells associated with reduced overall survival in a
small series of primary melanoma [13].
In loco-regional metastases, VPI was lower than in paired primary tumors, with no prog-
nostic impact. These findings indicate that whereas activated angiogenesis appears to be
important for expansion of the primary tumor, it might not be as significant at the metastatic
stage. In contrast, we found that the MVD level was significantly higher in metastatic lesions
than in paired primary tumors. At least for lymph node metastases, a possible explanation for
this opposite relationship could be that neo-angiogenesis is not required in the already highly
Table 4. Tumor necrosis in association with VPI and tumor diameter in loco-regional skin and lymph node
metastases.





Necrosis in loco-regional skin metastases (n = 25)
Absent Present p-valuea






Necrosis in loco-regional lymph node metastases (n = 48)
Absent Present p-valuea
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vascularized lymph nodes, and that metastatic tumor tissue might be supported by other
mechanisms such as vascular co-option [43]. Interestingly, a previous study from our group
demonstrated that VEGF-A was associated with pMVD and VPI in primary melanoma, and
with MVD in melanoma metastases [44]. A similar finding of reduced VPI in lymph node
metastases compared to primary tumors has recently been shown in breast cancer by our
group (Aziz et al, personal communication). In contrast, Pastushenko et al found that the
degree of blood vessel proliferation in sentinel lymph node metastases was significantly higher
Fig 4. Survival by uPAR expression. Survival by uPAR expression in primary melanoma (upper panel) and metastatic
tumors (lower panel), categorized according to the median in primary melanoma (SI 0–3 versus 4–9).
https://doi.org/10.1371/journal.pone.0210399.g004
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than in primary melanoma, and associated with reduced overall survival [14]. This might indi-
cate a larger demand for neo-angiogenesis in the newly established sentinel lymph node metas-
tases compared to the larger and more advanced non-sentinel lymph node tumors analyzed in
our series.
Fig 5. Survival by vascular proliferation. Survival by VPI in primary melanoma (upper panel) and metastatic tumors
(lower panel), categorized according to the lower quartile in primary melanoma (5.7%).
https://doi.org/10.1371/journal.pone.0210399.g005
uPAR Expression and angiogenesis in melanoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0210399 January 14, 2019 12 / 18
Fig 6. Survival by tumor necrosis. Survival by presence of tumor necrosis in loco-regional melanoma metastases.
https://doi.org/10.1371/journal.pone.0210399.g006
uPAR Expression and angiogenesis in melanoma
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Here, we show for the first time that high expression of uPAR in primary melanoma was
associated with reduced patient survival, and related to aggressive tumor features such as
increased thickness, mitotic count and tumor necrosis. In addition, uPAR was significantly
associated with high VPI, which is consistent with previous reports on the role of uPAR in
angiogenesis [22–24]. The functional study by Matheis et al. demonstrated that silencing of
uPAR lead to apoptosis in melanoma cells, which could support our finding of a prognostic
value of uPAR in primary tumors [45]. In loco-regional metastases, uPAR showed no prognos-
tic value or association with VPI, although we found a significant association with overall
microvessel density (MVD), indicating that uPAR-driven neo-angiogenesis and invasiveness
are more important in primary melanoma than in the loco-regional metastases. In summary,
our findings support a role of uPAR in primary melanoma angiogenesis and progression.
Presence of tumor necrosis, an indicator of tumor hypoxia, has shown a consistent associa-
tion with reduced patient survival in several different cancer types [46], and our group previously
reported a prognostic value in primary melanoma, as a novel observation [32, 33]. The present
study is the first to investigate tumor necrosis in melanoma loco-regional metastases. We found
a striking prognostic value in both skin and lymph node metastases. Presence of necrosis was
associated with high VPI in both lymph node lesions and in the primary tumor. Tumor necrosis
accompanied by presence of high vascularization has also been observed previously in different
cancer types [12, 47–50]. Importantly, tumor necrosis is regarded to develop as a response to
intra-tumoral hypoxia [51]. Angiogenesis can be induced by hypoxia directly through HIF1α
[52–54], but has also been described as a secondary process to tumor necrosis, induced by
inflammatory cytokines from necrotic cells [55–57]. Presence of necrosis was significantly asso-
ciated with increased tumor diameter in skin metastases and tended to show a similar association
in lymph node metastases. This may suggest that inadequate vascularization due to rapid tumor
growth is related to the development of tumor necrosis in those tumors. Thus, the adverse prog-
nostic value of tumor necrosis could be due to its relation to fast growing, inadequately vascular-
ized tumors, or to the active role of tumor necrosis in promoting angiogenesis and tumor
progression by the release of pro-inflammatory cytokines from necrotic cells [55–57].
In conclusion, we identified high uPAR expression and VPI as novel markers of reduced
cancer specific survival in primary melanoma, and confirmed an association of uPAR with
angiogenesis. This supports the importance of vascular proliferation in melanoma aggres-
siveness and progression, and suggests uPAR as an indicator of angiogenesis at least at the
stage of primary tumors.
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